piperacillin--tazobactam-drug-combination and Head-and-Neck-Neoplasms

Although perioperative antibiotic prophylaxis has significantly reduced surgical wound infection rates, this complication is still a frequent complication of head and neck cancer surgery. Because these infections are typically polymicrobial, our study evaluated the safety and efficacy of piperacillin-tazobactam in the treatment of surgical wound infection after clean-contaminated head and neck oncologic surgery.. In this multicenter, prospective clinical trial, 70 patients with surgical wound infection received piperacillin-tazobactam.. Of patients who were evaluable, 92.4% were also clinically cured or improved, and the bacteriologic eradication rate was 80.3%. Of the 70 patients enrolled in the study, six (8.5%) experienced six adverse events: two cases of moderate diarrhea, one allergic skin reaction, and three cases of phlebitis. No deaths were attributable to the study drug.. Piperacillin-tazobactam is a good choice of treatment as monotherapy for surgical wound infection after clean-contaminated head and neck oncologic surgery.

Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Female; Gram-Negative Bacterial Infections; Gram-Positive Bacterial Infections; Head and Neck Neoplasms; Humans; Male; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Prospective Studies; Surgical Wound Infection; Treatment Outcome